We show that this signaling axis is operative across different types of human cancer and may affect additional tumor contexts given that SOX2 is expressed and implicated in at least 20 types of human cancer [1] and MYC is deregulated in up to 70% of cancers [42]. Here, SOX2 is linked to neoplasm.